AstraZeneca (AZN) shares dip despite beating Q1 forecasts with $15.29B revenue. Analysts say strong results were already baked into the stock price. The post Why AstraZeneca (AZN) Stock Fell Despite Crushing Q1 Earnings Expectations appeared first on Blockonomi.
Source link
Be the first to comment